# Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

> **NCT05832333** · — · COMPLETED · sponsor: **Sanofi** · enrollment: 682 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** VaxigripTetra®

## Key facts

- **NCT ID:** NCT05832333
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-05
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-02-07
- **Target enrollment:** 682 (ACTUAL)
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832333, "Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05832333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*